Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maud Teyssandier"'
Autor:
Bagirath Gangadharan, Mathieu Ing, Sandrine Delignat, Ivan Peyron, Maud Teyssandier, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes
Publikováno v:
Haematologica, Vol 102, Iss 2 (2017)
The development of inhibitory antibodies to therapeutic factor VIII is the major complication of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti-factor VIII immune response is factor VIII interaction wi
Externí odkaz:
https://doaj.org/article/9ebd496e0534438787f8552fd1754402
Autor:
Maud Teyssandier, Sandrine Delignat, Julie Rayes, Marijke Bryckaert, Martine Jandrot-Perrus, Srini V. Kaveri, Sébastien Lacroix-Desmazes
Publikováno v:
Haematologica, Vol 97, Iss 7 (2012)
Externí odkaz:
https://doaj.org/article/80a86f117b2f40f09146f235e93be886
Autor:
Srinivas V. Kaveri, Maud Teyssandier, Sébastien Lacroix-Desmazes, Jagadeesh Bayry, Sandrine Delignat, Ana-Maria Navarrete, Yohann Repessé, Suryasarathi Dasgupta, Sébastien André
Publikováno v:
Thrombosis and Haemostasis
Thrombosis and Haemostasis, Schattauer, 2017, 104 (12), pp.1093-1098. ⟨10.1160/TH10-05-0294⟩
Thrombosis and Haemostasis, 2017, 104 (12), pp.1093-1098. ⟨10.1160/TH10-05-0294⟩
Thrombosis and Haemostasis, Schattauer, 2017, 104 (12), pp.1093-1098. ⟨10.1160/TH10-05-0294⟩
Thrombosis and Haemostasis, 2017, 104 (12), pp.1093-1098. ⟨10.1160/TH10-05-0294⟩
SummaryThe immunogenicity of therapeutic factor VIII (FVIII) in patients with haemophilia A remains a critical issue in patient management. This review describes the immunological processes involved in the activation of the immune system against FVII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515f1f6847004b485cb4ca5eab22f253
https://www.hal.inserm.fr/inserm-02455574
https://www.hal.inserm.fr/inserm-02455574
Autor:
Mathieu Ing, Sébastien Lacroix-Desmazes, Ivan Peyron, Bagirath Gangadharan, Maud Teyssandier, Sandrine Delignat, Srinivas V. Kaveri
Publikováno v:
Haematologica. 102(2)
The development of inhibitory antibodies to therapeutic factor VIII is the major complication of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti-factor VIII immune response is factor VIII interaction wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9959352f6875c28f45962a4fcbb3722d
https://pubmed.ncbi.nlm.nih.gov/27758819
https://pubmed.ncbi.nlm.nih.gov/27758819
Autor:
Sébastien Lacroix-Desmazes, Yann Meslier, Srinivas V. Kaveri, Sébastien André, Maud Teyssandier
Publikováno v:
Immunology. 131:549-555
Replacement therapy with exogenous factor VIII (FVIII) to treat haemorrhages or used in prophylaxis induces inhibitory anti-FVIII immunoglobulin G (IgG) in some patients with haemophilia A. Therapeutic strategies to prevent the onset of the deleterio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9665dccf115055d003d53c1ec6e0f654
https://doi.org/10.1111/j.1365-2567.2010.03327.x
https://doi.org/10.1111/j.1365-2567.2010.03327.x
Autor:
Sébastien Lacroix-Desmazes, Bernard Maillere, Maud Teyssandier, Mathieu Ing, Marc Pallardy, Sandrine Delignat, Nimesh Gupta
Publikováno v:
Cellular Immunology
Cellular Immunology, Elsevier, 2016, 301, pp.40-48. ⟨10.1016/j.cellimm.2015.12.006⟩
Cellular Immunology, 2016, 301, pp.40-48. ⟨10.1016/j.cellimm.2015.12.006⟩
Cellular Immunology, Elsevier, 2016, 301, pp.40-48. 〈10.1016/j.cellimm.2015.12.006〉
Cellular Immunology, Elsevier, 2016, 301, pp.40-48. ⟨10.1016/j.cellimm.2015.12.006⟩
Cellular Immunology, 2016, 301, pp.40-48. ⟨10.1016/j.cellimm.2015.12.006⟩
Cellular Immunology, Elsevier, 2016, 301, pp.40-48. 〈10.1016/j.cellimm.2015.12.006〉
International audience; Replacement therapy for patients with hemophilia A using plasma-derived or recombinant factor VIII (FVIII) is complicated by the short half-life of the FVIII products and by the occurrence of neutralizing antibodies in a subst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d98f066d1874aef4978be25dcef63b
https://pubmed.ncbi.nlm.nih.gov/26723503
https://pubmed.ncbi.nlm.nih.gov/26723503
Autor:
Yann, Meslier, Sébastien, André, Maud, Teyssandier, Srinivas V, Kaveri, Sébastien, Lacroix-Desmazes
Publikováno v:
Immunology. 131(4)
Replacement therapy with exogenous factor VIII (FVIII) to treat haemorrhages or used in prophylaxis induces inhibitory anti-FVIII immunoglobulin G (IgG) in some patients with haemophilia A. Therapeutic strategies to prevent the onset of the deleterio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::022fdefe1af06609cd6c96154e1c594a
https://pubmed.ncbi.nlm.nih.gov/20673239
https://pubmed.ncbi.nlm.nih.gov/20673239
Autor:
Maud Teyssandier, Sébastien André, Ana-Maria Navarrete, Srini V. Kaveri, Yann Meslier, Frédéric Triebel, Sandrine Delignat, Sébastien Lacroix-Desmazes, Jagadeesh Bayry
Publikováno v:
Arthritis & Rheumatism. 60:2848-2849
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0f204c7b1c94a160425686f27d7774b
https://doi.org/10.1002/art.24784
https://doi.org/10.1002/art.24784